5 mg Ivabradine Tablet Blister.jpg (5 mg Ivabradine Tablet Blister)
Ivabradine Tablet, Film Coated
Product Images NDC 60687-862
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 60687-862). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
5 mg Ivabradine Tablets Carton.jpg (5 mg Ivabradine Tablets Carton)
This text provides information about Ivabradine tablets with NDC code 60687-862-21, each tablet containing 5 mg or 7.5 mg of Ivabradine hydrochloride for oral use. The package includes 30 tablets (3 x 10) with storage instructions of 20° to 25°C. It also identifies the manufacturer as Chamber Pharmaceuticals Inc., and the distributor as American Health Packaging. The provided dosage instructions and a caution to not use if the blister is torn or broken are also highlighted.*
Figure 4 (Figure 4)
This is a data table showing the distribution of various demographics and health factors among participants in a study comparing Ivabradine to a placebo for heart failure. The table includes information on age, sex, race, cause of heart failure, weight, baseline heart rate, NYHA Class, baseline LV ejection fraction, baseline beta-blocker use, aldosterone antagonist use, diabetes history, and hypertension history. The data is presented in percentages for each category and quartile. The table also includes hazard ratios with 95% confidence intervals for different variables. This information can be valuable for understanding the characteristics of the study population and the potential impact of these factors on the outcomes of the study.*
Figure 2 (Ivabradinetabfig2)
This text lists the medication changes due to different inhibitors and inducers. It includes strong CYP3A4 inhibitors like Ketoconazole, moderate CYP3A4 inhibitors such as Diltiazem and Verapamil (along with Grapefruit Juice interaction), a CYPIAS inducer like St. John's Wort, and various other medications like Sidenafil, Lacidipine, Simvastatin, Lansoprazole, Omeprazole, and Warfarin with their respective dosages.*
Figure 3 (Ivabradinetabfig3)
This text appears to show data related to a clinical trial comparing a placebo group with an Ivabradine group over a certain period of time. The information includes the number of subjects at risk in each group at different time points (6, 12, 18 months), as well as the timeline from randomization in months. The data seems to be part of a study report but does not provide a detailed analysis.*
Chemical Structure (Ivabradinetabstructure)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
